APA (7th ed.) Citation

Graham, C. N., Maglinte, G. A., Schwartzberg, L. S., Price, T. J., Knox, H. N., Hechmati, G., . . . Fakih, M. G. (2016). Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy. Clinical therapeutics, 38(6), 1376-1391. https://doi.org/10.1016/j.clinthera.2016.03.023

Chicago Style (17th ed.) Citation

Graham, Christopher N., Gregory A. Maglinte, Lee S. Schwartzberg, Timothy J. Price, Hediyyih N. Knox, Guy Hechmati, Jonas Hjelmgren, Beth Barber, and Marwan G. Fakih. "Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy." Clinical Therapeutics 38, no. 6 (2016): 1376-1391. https://doi.org/10.1016/j.clinthera.2016.03.023.

MLA (9th ed.) Citation

Graham, Christopher N., et al. "Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy." Clinical Therapeutics, vol. 38, no. 6, 2016, pp. 1376-1391, https://doi.org/10.1016/j.clinthera.2016.03.023.